1. Academic Validation
  2. Vitamin D3 analogues that contain modified A- and seco-B-rings as hedgehog pathway inhibitors

Vitamin D3 analogues that contain modified A- and seco-B-rings as hedgehog pathway inhibitors

  • Eur J Med Chem. 2015 Mar 26:93:156-71. doi: 10.1016/j.ejmech.2015.01.049.
Albert M DeBerardinis 1 Daniel S Raccuia 1 Evrett N Thompson 1 Chad A Maschinot 1 M Kyle Hadden 2
Affiliations

Affiliations

  • 1 Department of Pharmaceutical Sciences, University of Connecticut, 69 N Eagleville Rd, Unit 3092, Storrs, CT 06269-3092, USA.
  • 2 Department of Pharmaceutical Sciences, University of Connecticut, 69 N Eagleville Rd, Unit 3092, Storrs, CT 06269-3092, USA. Electronic address: kyle.hadden@uconn.edu.
Abstract

The Hedgehog (Hh) signaling pathway is a developmental signaling pathway that has been implicated as a target for anti-cancer drug development in a variety of human malignancies. Several natural and synthetic vitamin D-based seco-steroids have been identified as potent inhibitors of Hh signaling with chemotherapeutic potential. These include the previously characterized analogue 4, which contains the northern CD-ring/side chain region of vitamin D3 (VD3) linked to an aromatic A-ring mimic through an ester bond. To further explore structure-activity relationships for this class of VD3-based Hh pathway inhibitors, we have designed, synthesized and evaluated several series of compounds that modify the length, composition, and stereochemical orientation of the ester linker. These studies have identified compounds 54 and 55, which contain an amine linker and an aromatic A-ring incorporating a para-phenol, as new lead compounds with enhanced potency against the Hh pathway (IC50 values = 0.40 and 0.32 μM, respectively).

Keywords

Basal cell carcinoma; Gli; Hedgehog signaling pathway; Medulloblastoma; Vitamin D3.

Figures
我们的 Cookie 政策

我们使用 Cookies 和类似技术以提高网站的性能和提升您的浏览体验,部分功能也使用 Cookies 帮助我们更好地理解您的需求,为您提供相关的服务。 如果您有任何关于我们如何处理您个人信息的疑问,请阅读我们的《隐私声明》